Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and tolerability of cobicistat-boosted darunavir plus
two fully active nucleoside analogue reverse transcriptase inhibitors in HIV 1 infected,
antiretroviral treatment-naive and treatment-experienced adults with no darunavir (DRV)
resistance-associated mutations.
After the Week 48 Visit, participants will be given the option to participate in an
open-label rollover phase to receive cobicistat and attend visits every 12 weeks until it
becomes commercially available, or until Gilead Sciences elects to terminate development of
cobicistat.